Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clenbuterol in Late-onset Pompe Disease
NCT01942590Phase 2Completed
- Start
- Sep 2013
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Pompe disease comparing Clenbuterol with Placebo (2 arms). Primary endpoints: Creatine Kinase at 52 weeks and Aspartate Aminotransferase, Alanine Transaminase, and Bilirubin at 52 weeks. Started Sep 2013; status: completed.
02
Drugs
clenbuterol
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT01942590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01942590.